论文部分内容阅读
In the past decade,an increased amount of clinicallyloriented research involving immunotoxins has been published.Immunotoxins are a group of artificially-made cytotoxic molecules targeting cancer cells.These moleculescomposed of a targeting moiety,such as a ligand or an antibody,linked to toxin moiety,which is a toxin with eithertruncated or deleted cell-binding domain that prevents it from binding to normal cells.Immunotoxins can bedivided into two categories:chemically conjugated immunotoxins and recombinant ones.The immunotoxins of thefirst category have shown limited efficacy in clinical trials in patients with hematologic malignancies and solidtumors.Within the last few years,single-chain immunotoxins provide enhanced therapeutic efficacy overconjugated forms and result in improved antitumor activity.In this review,we briefly illustrate the design of theimmunotoxins and their applications in clinical trials.Cellular & Molecular Immunology.2005;2(2):106-112.
In the past decade, an increased amount of clinicallyloriented research involving immunotoxins has been published. Immunotoxins are a group of artificially-made cytotoxic molecules targeting cancer cells. These molecules areposed on a targeting moiety, such as a ligand or an antibody, linked to toxin moiety , which is a toxin with eithertruncated or deleted cell-binding domain that prevents it from binding to normal cells. Immunoconoxins and can be divided into two categories: chemically conjugated immunotoxins and recombinant ones. The immunotoxins of thefirst category have shown limited efficacy in clinical trials in patients with hematologic malignancies and solid tumors. Whithin the last few years, single-chain immunotoxins provide enhanced therapeutic efficacy overconjugated forms and results in improved antitumor activity. this review, we illustrate illustrate the design of the immunotoxins and their applications in clinical trials. Cellular & Molecular Immunology. 2005; 2 (2): 106-112.